Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Drug application of L(r) salbutamol preparation in the treatment of skin and mucous membrane wound ulcer

A technology of levalbuterol and skin wound surface, applied in the field of preparations of levalbuterol medicinal salts and combinations thereof, and can solve problems such as unreported levalbuterol and the like

Active Publication Date: 2018-02-02
SUZHOU JUNNING NEW MEDICINE DEV CENT CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the existing literature does not report whether levosalbutamol can inhibit skin tissue ulcers and (or combined) bacterial infections caused by external trauma, burns, scalds, tumors, diabetes or infection, and whether it can promote wound wounds caused by the above reasons. heal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug application of L(r) salbutamol preparation in the treatment of skin and mucous membrane wound ulcer
  • Drug application of L(r) salbutamol preparation in the treatment of skin and mucous membrane wound ulcer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Preparation of Levalbuterol Cream

[0017] The preparation method of levalbuterol cream is as follows: prepare hydrophobic phase: accurately weigh 5% petrolatum, 10% paraffin oil, 5% gelatin, 6% glyceryl monostearate, 0.5 Tween80, heat to 70°C .

[0018] Preparation of the hydrophilic phase: accurately weigh 0.5% levosalbutamol sulfate, 5% propylene glycol, and 0.5% benzyl alcohol, and add water to 73.5%. Heat to 70°C. The two phases are mixed, and the mixture is cooled under stirring, and the levosalbutamol ointment is obtained. The ratio of levosalbutamol and auxiliary materials can also be adjusted according to demand, such as from 0.01%-99%. Salbutamol.

Embodiment 2

[0020] Experimental Study of Levo-Salbutamol Sulfate Ointment on Skin Wounds of Mice

[0021] 60 KM mice weighing 25-29g were randomly assigned to four experimental groups A, B, C, and D, with 15 mice in each group, and an acute trauma model was created in the depilated area of ​​the skin on the back of the mice, using a circular punch A full-thickness skin excision is made, creating a circular hole with a diameter of 8 mm (or two incisions, one on the back and one on the buttocks). Raised in separate cages. Groups A, B, C and D were smeared with self-made levosalbutamol ointment, blank excipients and positive control drug (ofloxacin) respectively. Administration method: Administer once a day (extension to 2-3mm, thickness about 0.5mm).

[0022] Observe the morphological changes of the wound every day, take pictures and measure the diameter of the wound, and record the time of scab formation and healing of the wound. The healing was defined as the wound surface was closed, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided in the present invention is an (R)-albuterol pharmaceutically acceptable salt or pharmaceutical formulation thereof, and the application thereof in the preparation of drugs for the treatment of diseases such as skin ulcers, lesions, purulence, or delayed healing caused by trauma, pressure sores, tumours, diabetes, or coinfection. The pharmaceutical formulation contains the levalbuterol pharmaceutically acceptable salt, or the levalbuterol pharmaceutically acceptable salt and hormones, antibiotics, or anti-inflammatory drugs.

Description

technical field [0001] The present invention relates to medicaments, in particular to the preparation of L-(R) salbutamol medicinal salt and its combination, and its application in the treatment of skin damage, ulcers and delayed healing caused by trauma, burns, bedsores, tumors, diabetes and the like. Background technique [0002] Racemic albuterol is a beta-receptor agonist containing a chiral center with opposite optical properties [0003] Enantiomers - R (left-handed) configuration albuterol and S (dextrorotary) configuration albuterol. Pharmacological studies have found that: R-configuration salbutamol and racemic salbutamol can ease the response of the pulmonary airway to some spasm-causing agents, that is, promote the relaxation of tracheal smooth machinery, while S-configuration salbutamol can not only relax tracheal smooth muscle but also in some Sometimes it will also aggravate bronchoconstriction; through experiments on human bronchi in vitro, it is found that S...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/137A61P17/02
CPCA61K31/137
Inventor 徐玲谭以知谭律雅
Owner SUZHOU JUNNING NEW MEDICINE DEV CENT CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products